Basic Stats
| CIK | 1018735 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NYMOX PHARMACEUTICAL CORP
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| June 3, 2025 |
EXHIBIT 12 (b) CERTIFICATION I, Patrick A. Doody, Vice President and General Counsel of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this annual report for the period ended December 31, 2024 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| June 3, 2025 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| June 3, 2025 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| June 3, 2025 |
EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| June 3, 2025 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Patrick A. Doody, VP and General Counsel of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut |
|
| May 1, 2025 |
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response...… … .2.50 FORM 12b-25 SEC FILE NUMBER CUSIP NUMBER NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transit |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2025 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exec |
|
| March 11, 2025 |
Nymox Pharmaceutical Corporation EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Dismissal of Delaware Action Against Ascella IRVINE CA, March 11, 2025 (Globe Newswire). Nymox announces that it dismissed the Delaware matter pending against Ascella on March 7, 2025. A number of factors caused the company to reconsider its strategy to |
|
| January 2, 2025 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2024 and 2023. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| January 2, 2025 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2024 Commission File Number: 001-12033 NYMOX PHARMACEUTICAL CORPORATION Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| January 2, 2025 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2024 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal e |
|
| December 17, 2024 |
Nymox Pharmaceutical Corporation EX-99.1 2 nymoxex991.htm PRESS RELEASE EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX Announces Trading Resumed and New Listing on OTCQB Market IRVINE CA, December 17, 2024. Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that the Company's stock has resumed trading under the sym |
|
| August 29, 2024 |
EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| August 29, 2024 |
EXHIBIT 12 (b) CERTIFICATION I, Patrick A. Doody, Vice President and General Counsel of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this annual report for the period ended December 31, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the |
|
| August 29, 2024 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Patrick A. Doody, VP and General Counsel of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the |
|
| August 29, 2024 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| August 29, 2024 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu |
|
| July 18, 2024 |
Nymox Pharmaceutical Corporation EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Annual Report IRVINE CA, July 18, 2024. Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its Annual Report is and has been in progress since late February, soon after Nymox received some of its corporate documents withheld by the |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu |
|
| July 16, 2024 |
EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Required to Resubmit Application to DKMA IRVINE CA, July 16, 2024. Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets NYMXF) announced today that its MAA submission to the Danish Medicines Agency (DKMA) has run out of time and in order to continue will be requ |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut |
|
| May 13, 2024 |
EXHIBIT 99.1 May 13, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Nymox Pharmaceutical Corporation Ladies and Gentlemen: We have read Nymox Pharmaceutical Corporation’s Form 6-K dated May 13, 2024, and we agree with the statements set forth in the Form 6-K, insofar as they relate to our firm. We have no basis to agree or disagr |
|
| March 28, 2024 |
EXHIBIT 99.1 |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March, 2024 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exec |
|
| November 15, 2023 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2023 and 2022. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| November 15, 2023 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 15, 2023 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| November 9, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Pharmaceutical Corporation Sues AscellaHealth For $250 Million IRVINE CA, November 9, 2023. This week, Nymox Pharmaceutical Corporation (“Nymox”) (OTC Markets - NYMXF) was forced to file a lawsuit in California Superior Court, Orange County, to protec |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal e |
|
| November 6, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.1 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Notice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder Meeting IRVINE, CA (October 27, 2023) -The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Mar |
|
| November 6, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.3 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: IMPORTANT MESSAGE TO NYMOX SHAREHOLDERS: NYMOX Cautions Against Unauthorized Improper Shareholder Meeting and Unauthorized Unregistered Solicitations IRVINE CA, November 2, 2023. The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceuti |
|
| November 6, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.4 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023 Ex-Employees and Agents, and those working in concert with them, are order |
|
| November 6, 2023 |
EXHIBIT 99.2 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: IMPORTANT NOTICE: NYMOX Cautions Shareholders Not to Take Calls or Participate in Unauthorized Improper Shareholder Meeting IRVINE CA, October 31, 2023. The following is Nymox's response to an unauthorized shareholder meeting: Nymox Pharmaceutical Corporation [OTC Marke |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Months of October and November, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address o |
|
| November 6, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.5 For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX REPORTS: Bahamian Court Today Suspends Order of October 3, 2023 Rendering Riley-Lanham and Accomplices Planned Vote Unauthorized IRVINE CA, November 3, 2023. Nymox Pharmaceutical Corporation (“Nymox” or the "Company") [OTC Markets-NYMXF] is pleased to announce tha |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of October, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal ex |
|
| October 26, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For Review IRVINE, CA (October 26, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Trifluta |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal |
|
| September 25, 2023 |
EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH IRVINE, CA (September 25, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce today that a new forma |
|
| August 29, 2023 |
EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Reports Completion of $2 Million Private Placement IRVINE, CA (August 29, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the completion of its recently reported private placement of USD 2 million. T |
|
| August 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exe |
|
| August 14, 2023 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig |
|
| August 14, 2023 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2023 and 2022. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This |
|
| August 14, 2023 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ |
|
| August 2, 2023 |
EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces $2 Million Private Placement IRVINE, CA (August 2, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce an investment of US $2.0 million for 2 million shares at the price of $1.00 per share with |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal exe |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu |
|
| July 31, 2023 |
EXHIBIT 99.1 |
|
| July 25, 2023 |
EXHIBIT 99.1 |
|
| July 25, 2023 |
EXHIBIT 99.1 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu |
|
| July 25, 2023 |
EXHIBIT 99.2 |
|
| July 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execu |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut |
|
| July 12, 2023 |
EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox IRVINE, CA (July 12, 2023) Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick |
|
| July 6, 2023 |
Nymox Pharmaceutical Corporation EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Delisting from NASDAQ IRVINE, CA (July 5, 2023) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month exten |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation (Translation of registrant’s name into English) Bay & Deveaux Streets, Nassau, The Bahamas (Address of principal execut |
|
| May 12, 2023 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| May 12, 2023 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| May 12, 2023 |
EXHIBIT 99.3 CERTIFICATION I, Christopher Riley, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2023 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| May 12, 2023 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2023 and 2022. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is |
|
| May 2, 2023 |
EXHIBIT 12 (b) CERTIFICATION I, Randall J. Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this annual report for the period ended December 31, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of t |
|
| May 2, 2023 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| May 2, 2023 |
EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| May 2, 2023 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| May 2, 2023 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Randall J. Lanham, COO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended Decem |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 000-54332 CUSIP NUMBER (Check one): ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Re |
|
| January 6, 2023 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended January 4, 2023 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| November 16, 2022 |
Quarterly Report for the Quarter ended September 30, 2022 EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2022 and 2021. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| November 16, 2022 |
Amendment No. 1 FORM 6-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or |
|
| November 16, 2022 |
EX-99.3 4 nymoxex993.htm CFO CERTIFICATION EXHIBIT 99.3 CERTIFICATION I, Randall J, Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessa |
|
| November 16, 2022 |
Amendment No. 1 FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 10, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Fo |
|
| November 16, 2022 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 14, 2022 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 14, 2022 |
EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and nine months ended September 30, 2022 and 2021. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| November 14, 2022 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 10, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20 |
|
| November 14, 2022 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| November 14, 2022 |
EXHIBIT 99.3 CERTIFICATION I, Randall J, Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| August 15, 2022 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and six months ended June 30, 2022 and 2021. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This |
|
| August 15, 2022 |
EXHIBIT 99.3 CERTIFICATION I, Randall J, Lanham, COO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the |
|
| August 15, 2022 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in lig |
|
| August 15, 2022 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ? |
|
| July 8, 2022 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 28, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ? |
|
| May 13, 2022 |
EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as at and for the three months ended March 31, 2022 and 2021. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is |
|
| May 13, 2022 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| May 13, 2022 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2022 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci |
|
| May 13, 2022 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| April 6, 2022 |
NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas April 6, 2022 NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas April 6, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| March 30, 2022 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| March 30, 2022 |
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 30, 2022 |
Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 30, 2022 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 20-F ☐ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| March 30, 2022 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| March 29, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 29, 2022 |
EXHIBIT 107 FILING FEE TABLE CALCULATION OF REGISTRATION FEE Title Of Each Class Of Securities To Be Registered Amount To Be Registered (1)(2) Proposed Maximum Offering Price Per Share (1)(2) Proposed Maximum Aggregate Offering Price Amount Of Registration Fee (2) Common shares stock issuable upon exercise of warrants, No Par Value(1) 3,878,789 $ 1. |
|
| March 22, 2022 |
EXHIBIT 99.1 NEWS RELEASE For Further Information Contact: Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com Nymox Announces Closing of $6.4 Million Registered Direct Offering IRVINE, CA (March 22, 2022) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced the upsizing and closing of its previously announced offering to institutional and accredited investors consisting of 3,8 |
|
| March 22, 2022 |
EXHIBIT 10.2 March 18, 2022 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, the Bahamas Attn: Erik Danielsen, Chief Financial Officer Dear Mr. Danielsen: Re: Registered Direct Offering of Common Stock and Concurrent Private Placement of Common Stock Purchase Warrants This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent |
|
| March 22, 2022 |
EX-10.1 5 nymoxex101.htm EX-10.1 EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 18, 2022, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and |
|
| March 22, 2022 |
Nymox Pharmaceutical Corporation Filed Pursuant to Rule 424(b)(5) Registration No. 333-261571 PROSPECTUS SUPPLEMENT (to Prospectus dated January 28, 2022) Nymox Pharmaceutical Corporation We are offering 3,878,789 shares of common stock, no par value per share, to several institutional and accredited investors pursuant to this prospectus supplement and the accompanying prospectus and a securities purchase agreement with such inve |
|
| March 22, 2022 |
Form of Placement Agent Warrant EX-4.2 3 nymoxex42.htm EX-4.2 EXHIBIT 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PU |
|
| March 22, 2022 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| March 22, 2022 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 22, 2022 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| January 25, 2022 |
NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas January 25, 2022 CORRESP 1 filename1.htm NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas January 25, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Nymox Pharmaceutical Corporation Registration Statement on Form F-3 File No. 333-261571 Acceleration Request Requested Date: January 28, 2022, 11:00 am Eastern Standard Ti |
|
| December 9, 2021 |
EXHIBIT 10.1 NYMOX PHARMACEUTICAL CORPORATION and , as Trustee INDENTURE Dated as of , 20 Providing for the Issuance of Debt Securities CROSS-REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) 6.09 (a)(2) 6.09 (a)(3) N.A. (a)(4) N.A. (a)(5) 6.09 (b) 6.08 311 (a) 6.13 (b) 6.13 312 (a) 7.01; 7.02 (b) 7.02 (c) 7.02 313 (a) 7.03; 1.02 (b) 7.03 (c) 7.03 (d) 7.03 314 (a) 7.04 (b) |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas Not applicable. (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Bay & Deveaux Streets Nassau, The Bahamas (Address of |
|
| December 9, 2021 |
EXHIBIT 10.3 December 3, 2021 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The Bahamas Ladies and Gentlemen: Reference is hereby made to that certain sales agreement (the ?Agreement?), dated as of July 17, 2020, by and between Nymox Pharmaceutical Corporation (the ?Company?) and A.G.P./Alliance Global Partners (?A.G.P.?). The Company and A.G.P. hereby agree to amend the Agreement |
|
| November 22, 2021 |
Notice of annual general meeting on December 14, 2021 EX-99.1 2 nymoxex991.htm EX-99.1 EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December |
|
| November 22, 2021 |
EXHIBIT 99.3 |
|
| November 22, 2021 |
EX-99.4 5 nymoxex994.htm EX-99.4 EXHIBIT 99.4 |
|
| November 22, 2021 |
FORM 6-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form |
|
| November 22, 2021 |
EX-99.2 3 nymoxex992.htm EX-99.2 EXHIBIT 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2021 This proxy circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in |
|
| November 19, 2021 |
EX-99.4 5 nymoxex994.htm EX-99.4 EXHIBIT 99.4 |
|
| November 19, 2021 |
NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2021 EX-99.2 3 nymoxex992.htm EX-99.2 EXHIBIT 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2021 This proxy circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in |
|
| November 19, 2021 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20 |
|
| November 19, 2021 |
EXHIBIT 99.3 |
|
| November 19, 2021 |
NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the ?Meeting?) of Nymox Pharmaceutical Corporation (the ?Corporation?) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 14, 2021, at 4:30 p.m. (EDT), fo |
|
| November 12, 2021 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 12, 2021 |
EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and nine months ended September 30, 2021 and 2020. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| November 12, 2021 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| November 12, 2021 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| August 13, 2021 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30,2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| August 13, 2021 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as of and for the three and six months ended June 30, 2021 and 2020. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This |
|
| August 13, 2021 |
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ |
|
| August 13, 2021 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| June 11, 2021 |
EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| June 11, 2021 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| June 11, 2021 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| June 11, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Amendment No. 1 Form 20?F ? Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ? Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition Report pursuant to section 13 or 15(d) of the Securitie |
|
| June 11, 2021 |
EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| May 17, 2021 |
NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas May 14, 2021 NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas May 14, 2021 Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| May 14, 2021 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci |
|
| May 14, 2021 |
6-K 1 nymox6k.htm FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20 |
|
| May 14, 2021 |
EX-99.2 3 nymoxex992.htm EX-99.2 EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2021 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary t |
|
| May 14, 2021 |
EXHIBIT 99.1 MANAGEMENT?S DISCUSSION AND ANALYSIS (in US dollars) This is Management?s discussion and analysis (?MD&A?) comments on the Corporation?s operations, performance and financial condition as at and for the three months ended March 31, 2021 and 2020. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is |
|
| May 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas Not applicable (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Bay & Deveaux Streets Nassau, The Bahamas Contact pe |
|
| May 6, 2021 |
Incorporated by Reference to the Report on 6-K filed May 6, 2021. EXHIBIT 10.1 EXECUTION COPY April 28, 2021 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, the Bahamas Attn: Erik Danielsen, Chief Financial Officer Dear Mr. Danielsen: Re: Private Placement of Common Stock and Common Stock Purchase Warrants This letter (the ?Agreement?) constitutes the agreement between A.G.P./Alliance Global Partners (the ?Placement Agent?) and Nymox Pharmaceutica |
|
| May 6, 2021 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended April 30, 2021 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| May 6, 2021 |
Form of Placement Agent Warrant EXHIBIT 4.2 COMMON STOCK PURCHASE WARRANT NYMOX PHARMACEUTICAL CORPORATION Warrant Shares: [ ] Initial Exercise Date: April 30, 2021 Issue Date: April 30, 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, pursuant to a Placement Agent Agreement by and between A.G.P./Alliance Global Partners (?Holder?), as registered owner of this Warrant and Nymox Pharmaceutical Corporation, |
|
| May 6, 2021 |
EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 6, 2021 |
EX-99.1 7 nymoxex991.htm EX-99.1 EXHIBIT 99.1 For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: NYMOX ANNOUNCES $8,000,000 PRIVATE PLACEMENT HASBROUCK HEIGHTS, NJ (April 28, 2021) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today announced it has entered into a definitive agreement with institutio |
|
| May 6, 2021 |
Registration Rights Agreement dated April 28, 2021 EX-10.3 6 nymoxex103.htm EX-10.3 EXHIBIT 10.3 EXECUTION COPY REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of April 28, 2021, by and between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each of the several purchasers signatory hereto (each |
|
| May 6, 2021 |
EX-10.2 5 nymoxex102.htm EX-10.2 EXHIBIT 10.2 EXECUTION COPY SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 28, 2021, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its |
|
| March 29, 2021 |
Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 29, 2021 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| March 29, 2021 |
United States Securities and Exchange Commission Washington, D.C. 20549 Form 20?F ? Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ? Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or ? Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| March 29, 2021 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| March 29, 2021 |
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| November 20, 2020 |
NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 21, 2020, at 4:30 p.m. (EDT), fo |
|
| November 20, 2020 |
NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2020 EXHIBIT 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 10, 2020 This proxy circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in Nassau Bahamas on December 21, 2 |
|
| November 20, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 19, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20 |
|
| November 20, 2020 |
EXHIBIT 99.3 |
|
| November 19, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended November 18, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20 |
|
| November 13, 2020 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 13, 2020 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| November 13, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| November 13, 2020 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2020 and 2019. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| October 13, 2020 |
EXHIBIT 16.1 United States Securities and Exchange Commission Office of the Chief Accountant 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the statements under Item 4.01 in the Form 6-K dated October 13, 2020, of Nymox Pharmaceutical Corp. (the “Company”) to be filed with the Securities and Exchange Commission and we agree with such statements therein as related to o |
|
| October 13, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended October 13, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20- |
|
| August 14, 2020 |
$9,000,000 Nymox Pharmaceutical Corporation Filed Pursuant to Rule 424(b)(5) Registration No. 333-237564 PROSPECTUS SUPPLEMENT (to Prospectus dated May 13, 2020) $9,000,000 Nymox Pharmaceutical Corporation We are offering 3,600,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus at an offering price of $2.50 per share. Our shares of common stock are traded on the Nasdaq Capital Market under |
|
| August 14, 2020 |
EXHIBIT 99.1 For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces Closing of $9 Million Registered Direct Offering HASBROUCK HEIGHTS, NJ (August 14, 2020) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced the closing of a registered direct offering of 3,600,000 shares of its common stock, a |
|
| August 14, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ |
|
| August 14, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended August 14, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| August 14, 2020 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2020 and 2019. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This |
|
| August 14, 2020 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| August 14, 2020 |
Nymox Pharmaceutical Corporation Up to $2,872,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-237564 AMENDMENT NO. 1 DATED AUGUST 12, 2020 to PROSPECTUS SUPPLEMENT DATED JULY 17, 2020 (to Prospectus dated May 13, 2020) Nymox Pharmaceutical Corporation Up to $2,872,000 Shares of Common Stock This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends and supplements the information in our prospectus supplement dated July 17, |
|
| August 14, 2020 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30,2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| August 14, 2020 |
EXHIBIT 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 12, 2020, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and coll |
|
| August 14, 2020 |
Placement Agent Agreement, dated August 12, 2020, between the Company and the Placement Agent EXHIBIT 10.1 August 12, 2020 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, the Bahamas Attn: Erik Danielsen, Chief Financial Officer Dear Mr. Danielsen: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent”) and Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of |
|
| August 13, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended August 11, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| August 13, 2020 |
EXHIBIT 99.1 July 30, 2020 Nymox Pharmaceutical Corporation Bay & Deveaux Streets Nassau, The Bahamas Re: Nymox Pharmaceutical Corporation Registration Statement on Form F-3 Ladies and Gentlemen: We have acted as special counsel to Nymox Pharmaceutical Corporation, a Bahamian corporation (the “Company”), in connection with the preparation and filing with the Securities and Exchange Commission (the |
|
| August 12, 2020 |
EXHIBIT 99.1 For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox Announces $9 Million Registered Direct Offering HASBROUCK HEIGHTS, NJ (August 12, 2020) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the pur |
|
| August 12, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended August 12, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| July 20, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended July 17, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ |
|
| July 20, 2020 |
NYMOX PHARMACEUTICAL CORPORATION COMMON STOCK SALES AGREEMENT EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION COMMON STOCK SALES AGREEMENT July 17, 2020 A.G.P./Alliance Global Partners 590 Madison Avenue New York, NY 10022 Ladies and Gentlemen: Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), confirms its agreement (this “Agreement”) with A.G.P./Alliance Global Partners, as |
|
| July 17, 2020 |
Nymox Pharmaceutical Corporation Up to $12,000,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-237564 PROSPECTUS SUPPLEMENT (to Prospectus dated May 13, 2020) Nymox Pharmaceutical Corporation Up to $12,000,000 Shares of Common Stock This prospectus supplement and accompanying prospectus relates to the issuance and sale of up to $12,000,000 of our common stock, no par value per share, from time to time through our sales agent, A.G.P. / Al |
|
| May 14, 2020 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci |
|
| May 14, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2020 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| May 14, 2020 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2020 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| May 14, 2020 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2020 and 2019. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is |
|
| May 7, 2020 |
NYMOX PHARMACEUTICAL CORPORATION Bay & Deveaux Streets, Nassau, The Bahamas May 7, 2020 Securities and Exchange Commission Division of Corporation Finance 100 F Street N. |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas The NASDAQ Stock Market, LLC (NASDAQ Capital Market) (State or other jurisdiction of incorporation or organization) (Name of each exchange on which eac |
|
| April 24, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas The NASDAQ Stock Market, LLC (NASDAQ Capital Market) (State or other jurisdiction of incorporation or organization) (Name of each exchange on which eac |
|
| April 24, 2020 |
Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended April 23, 2020 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F o Indicate by check ma |
|
| April 24, 2020 |
EXHIBIT 10 NYMOX PHARMACEUTICAL CORPORATION and , as Trustee INDENTURE Dated as of , 20 Providing for the Issuance of Debt Securities CROSS-REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310 (a)(1) 6. |
|
| April 3, 2020 |
NYMX / Nymox Pharmaceutical Corp. F-3 - - FORM F-3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NYMOX PHARMACEUTICAL CORPORATION (Exact name of registrant as specified in its charter) Bahamas The NASDAQ Stock Market, LLC (NASDAQ Capital Market) (State or other jurisdiction of incorporation or organization) (Name of each exchange on which each stock it to be |
|
| March 30, 2020 |
Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 30, 2020 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| March 30, 2020 |
NYMX / Nymox Pharmaceutical Corp. 20-F - - FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or ☒ Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 or ☐ Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| March 30, 2020 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| March 30, 2020 |
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| November 19, 2019 |
Filed by e3 Filing, Computershare 1-800-973-3274 - Nymox Pharmaceutical Corporation - Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 19, 2019 |
Proxies submitted must be received by 5:00 pm, Eastern Time, on December 14, 2019. Exhibit 99.3 Exhibit 99.3 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on December 17, 2019 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a ho |
|
| November 19, 2019 |
NYMOX PHARMACEUTICAL CORPORATION Exhibit 99.1 Exhibit 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 17, 2019, at 4:30 p |
|
| November 19, 2019 |
NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 15, 2019 Exhibit 99.2 Exhibit 99.2 NYMOX PHARMACEUTICAL CORPORATION MANAGEMENT PROXY CIRCULAR November 15, 2019 This proxy circular (the “Circular ”) is furnished in connection with the solicitation of proxies by the management of Nymox Pharmaceutical Corporation (the “Corporation”) for use at the Annual General Meeting of the shareholders of the Corporation (the “Meeting”) to be held in Nassau Bahamas on |
|
| November 13, 2019 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| November 13, 2019 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2019 and 2018. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| November 13, 2019 |
NYMX / Nymox Pharmaceutical Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2019 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| November 13, 2019 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| August 14, 2019 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2019 and 2018. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This |
|
| August 14, 2019 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| August 14, 2019 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30,2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| August 14, 2019 |
NYMX / Nymox Pharmaceutical Corp. 6-K - Current Report of Foreign Issuer - FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2019 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x |
|
| May 15, 2019 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2019 and 2018. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is |
|
| May 15, 2019 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci |
|
| May 15, 2019 |
NYMX / Nymox Pharmaceutical Corp. 6-K Current Report of Foreign Issuer FORM 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2019 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| May 15, 2019 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2019 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in li |
|
| March 29, 2019 |
NYMX / Nymox Pharmaceutical Corp. FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 or o Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| March 29, 2019 |
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 29, 2019 |
Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 29, 2019 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| March 29, 2019 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| November 24, 2018 |
Proxies submitted must be received by 5:00 pm, Eastern Time, on December 14, 2018. Exhibit 99.3 Exhibit 99.3 8th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on December 18, 2018 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of their choice, who need not be a ho |
|
| November 24, 2018 |
NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS Exhibit 99.2 Exhibit 99.2 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 18, 2018, at 4:30 p |
|
| November 24, 2018 |
NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS Exhibit 99.1 Exhibit 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the “Meeting”) of Nymox Pharmaceutical Corporation (the “Corporation”) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 18, 2018, at 4:30 p |
|
| November 24, 2018 |
Filed by e3 Filing, Computershare 1-800-973-3274 - Nymox Pharmaceutical Corporation - Form 6-K FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 13, 2018 |
EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of th |
|
| November 13, 2018 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 13, 2018 |
NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2018 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 2 |
|
| November 13, 2018 |
EXHIBIT 99.1 MANAGEMENT’S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and nine months ended September 30, 2018 and 2017. This MD&A should be read together with the unaudited interim Consolidated Financial Statements and the related notes. This MD&A |
|
| August 13, 2018 |
EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in ligh |
|
| August 13, 2018 |
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended June 30, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the cir |
|
| August 13, 2018 |
NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended June 30, 2018 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x |
|
| August 13, 2018 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This is Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as of and for the three and six months ended June 30, 2018 and 2017. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This |
|
| May 15, 2018 |
EXHIBIT 99.1 MANAGEMENT'S DISCUSSION AND ANALYSIS (in US dollars) This Management’s discussion and analysis (“MD&A”) comments on the Corporation’s operations, performance and financial condition as at and for the three months ended March 31, 2018 and 2017. This MD&A should be read together with the unaudited condensed interim Consolidated Financial Statements and the related notes. This MD&A is da |
|
| May 15, 2018 |
CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| May 15, 2018 |
EX-99.2 3 nymxex992.htm CEO CERTIFICATION CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended March 31, 2018 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to ma |
|
| May 15, 2018 |
NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended March 31, 2018 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F |
|
| May 11, 2018 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| May 11, 2018 |
Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| May 11, 2018 |
NYMX / Nymox Pharmaceutical Corp. FORM 20-F AMENDMENT NO. 1 United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F/A Amendment No. 1 ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 or o Transition Report pursuant to section 13 or 15(d) of the Securit |
|
| May 11, 2018 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| May 11, 2018 |
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| April 26, 2018 |
NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of April 2018 Nymox Pharmaceutical Corporation 1 St. Bay & Deveaux Streets Nassau, The Bahamas (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports un |
|
| March 30, 2018 |
NYMX / Nymox Pharmaceutical Corp. FORM 20-F United States Securities and Exchange Commission Washington, D.C. 20549 Form 20–F ¨ Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or x Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 or o Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act o |
|
| March 30, 2018 |
Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (b) CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 30, 2018 |
Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) EXHIBIT 12 (a) CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. |
|
| March 30, 2018 |
EXHIBIT 13 (a) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period e |
|
| March 30, 2018 |
EXHIBIT 13 (b) CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December |
|
| December 2, 2017 |
nymoxex992.htm EXHIBIT 99.2 |
|
| December 2, 2017 |
NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) nymox6k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For December 1, 2017 Nymox Pharmaceutical Corporation 1 St. Bay & Deveaux Streets Nassau, The Bahamas (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual repor |
|
| December 2, 2017 |
NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS nymoxex991.htm EXHIBIT 99.1 NYMOX PHARMACEUTICAL CORPORATION NOTICE OF THE ANNUAL GENERAL MEETING OF THE SHAREHOLDERS NOTICE IS HEREBY GIVEN that the Annual General Meeting of the shareholders (the ?Meeting?) of Nymox Pharmaceutical Corporation (the ?Corporation?) will be held at the British Colonial Hilton, Nassau Bahamas, Number One Bay St., Nassau Bahamas, on Tuesday, December 19, 2017, at 4:30 |
|
| November 6, 2017 |
NYMX / Nymox Pharmaceutical Corp. FORM 6-K (Current Report of Foreign Issuer) nymox6k.htm FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the period ended September 30, 2017 Commission File Number: 001-12033 Nymox Pharmaceutical Corporation Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form |
|
| November 6, 2017 |
nymoxex992.htm EXHIBIT 99.2 CERTIFICATION I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2017 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the sta |
|
| November 6, 2017 |
nymoxex993.htm EXHIBIT 99.3 CERTIFICATION I, Erik Danielsen, CFO of Nymox Pharmaceutical Corporation, certify that: 1. I have reviewed this quarterly report for the period ended September 30, 2017 of Nymox Pharmaceutical Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
